AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1550410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg twice daily
Number of subjects: 160
Study 1550410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 12 mg twice daily
Number of subjects: 160
Study 1550410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 1550410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg daily
Number of subjects: 160
Study 1550410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 12 mg daily
Number of subjects: 160
Study 2422742 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy (TURP)
Number of subjects: 75
Study 2422742 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvesical prostatectomy (TVP)
Number of subjects: 75
Study 29196436 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 15 mg
Number of subjects: 621
Study 29196436 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg
Number of subjects: 621
Study 29196436 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Number of subjects: 621
Study 27070534 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight hyaluronic acid (LMW‐HA) injection (Hyalgan®, 500‐730 kDa), 3 injections
Number of subjects: 34
Study 27070534 — intervention group
Group type: COMPARATOR
Intervention: Low-energy extracorporeal shock-wave therapy (ESWT), 4 sessions
Number of subjects: 34
Study 26122244 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (0.5 mg/kg BW, max 5 mg)
Number of subjects: 60
Study 26122244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23740007 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine (50 mg three times per day for 28 days)
Number of subjects: 294
Study 23740007 — intervention group
Group type: COMPARATOR
Intervention: Thermotherapy (Thermomed® application of 50 °C for 30 seconds over the lesion and surrounding area)
Number of subjects: 294
Study 21079465 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed catheter system with a specially designed Tegaderm dressing
Number of subjects: 302
Study 21079465 — intervention group
Group type: COMPARATOR
Intervention: StatLock device with a nonwinged catheter
Number of subjects: 302
Study 18435392 — intervention group
Group type: EXPERIMENTAL
Intervention: One Arm Group (both vaccines in one arm)
Number of subjects: 188
Study 18435392 — intervention group
Group type: COMPARATOR
Intervention: Two Arm Group (one vaccine in each arm)
Number of subjects: 188
Study 18435392 — intervention group
Group type: EXPERIMENTAL
Intervention: Neis Vac‐C (in Two Arm Group)
Number of subjects: 188
Study 18435392 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombivax HB (in Two Arm Group)
Number of subjects: 188
Study 16001131 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 0
Study 16001131 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 0
Study 12511765 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressive medication (exact dosage and duration not specified)
Number of subjects: 100
Study 10682151 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine combination therapy
Number of subjects: 29
Study 7815570 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 1 (seromuscular bowel flap tube) in 11 patients
Number of subjects: 17
Study 7815570 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 2 (full thickness bowel flap tube) in 6 patients
Number of subjects: 17
Study 7815570 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results for both techniques
Number of subjects: 17
Study 7815570 — intervention group
Group type: EXPERIMENTAL
Intervention: Seromuscular bowel flap tube
Number of subjects: 17
Study 1682533 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 28
Study 1682533 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 28
Study 1682533 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 28
Study 7027040 — intervention group
Group type: EXPERIMENTAL
Intervention: High-BUN group
Number of subjects: 151
Study 7027040 — intervention group
Group type: COMPARATOR
Intervention: Low-BUN group
Number of subjects: 151
Study 7027040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis treatment time (long or short)
Number of subjects: 151
Study 31141424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip mobilization with movement (MWM) technique
Number of subjects: 56
Study 31141424 — intervention group
Group type: COMPARATOR
Intervention: Sham mobilization
Number of subjects: 56
Study 30229461 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT‐ST plus TAU
Number of subjects: 95
Study 30229461 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 95
Study 28495391 — intervention group
Group type: EXPERIMENTAL
Intervention: Embodied Conversational Agent (ECA)
Number of subjects: 61
Study 28495391 — intervention group
Group type: COMPARATOR
Intervention: Patient education sheets plus a meditation CD/MP3
Number of subjects: 61
Study 25716637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 (50,000 IU weekly)
Number of subjects: 173
Study 25716637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 24016557 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A treatment
Number of subjects: 1024
Study 24016557 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B treatment
Number of subjects: 1024
Study 24016557 — intervention group
Group type: EXPERIMENTAL
Intervention: Type C treatment
Number of subjects: 1024
Study 24016557 — intervention group
Group type: EXPERIMENTAL
Intervention: Type D treatment
Number of subjects: 1024
Study 24016557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Glucocorticoid)
Number of subjects: 1024
Study 24016557 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment results
Number of subjects: 1024
Study 20608918 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass AIT (Grazax, Phleum pratense, 75,000 SQ-T/2,800 BAU)
Number of subjects: 634
Study 20608918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 634
Study 19586145 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial-Winning condition
Number of subjects: 179
Study 19586145 — intervention group
Group type: COMPARATOR
Intervention: Initial-Losing condition
Number of subjects: 179
Study 18087552 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (480 mg/d)
Number of subjects: 60
Study 18087552 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg/d)
Number of subjects: 60
Study 15476904 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg once daily for 12 months
Number of subjects: 116
Study 15476904 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS 20 mg once daily for 12 months
Number of subjects: 116
Study 11810363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg/kg
Number of subjects: 80
Study 11810363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 80
Study 9916610 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate ophthalmic gel-forming solution 0.5% QD
Number of subjects: 152
Study 9916610 — intervention group
Group type: COMPARATOR
Intervention: Levobunolol hydrochloride 0.5% BID
Number of subjects: 152
Study 7482139 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical gloves
Number of subjects: 0
Study 7482139 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove leak and contamination studies
Number of subjects: 0
Study 7482139 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 2707923 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral ciprofloxacin
Number of subjects: 6
Study 2707923 — intervention group
Group type: COMPARATOR
Intervention: 200 mg intravenous ciprofloxacin
Number of subjects: 6
Study 665536 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 50
Study 665536 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 50
Study 665536 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (inoperable patients)
Number of subjects: 50
Study 665536 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (patients without significant coronary artery disease)
Number of subjects: 50
Study 665536 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (incidence rate)
Number of subjects: 50
Study 31883370 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 168
Study 31883370 — intervention group
Group type: COMPARATOR
Intervention: Actoxumab + Bezlotoxumab
Number of subjects: 168
Study 31883370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 31135960 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-field digital mammography (FFDM)
Number of subjects: 9
Study 31135960 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital breast tomosynthesis (DBT)
Number of subjects: 9
Study 31135960 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic mammography (SM)
Number of subjects: 9
Study 27935735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) 70 mg/day for 5 weeks
Number of subjects: 21
Study 27935735 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (active moiety of LDX)
Number of subjects: 21
Study 27935735 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single-blind for 1 week prior to LDX)
Number of subjects: 21
Study 25937506 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Up for Healthy Living curriculum (intervention) consisting of eight 40-minute sessions focusing on nutrition awareness, physical activity, leadership, and communication.
Number of subjects: 10
Study 25937506 — intervention group
Group type: COMPARATOR
Intervention: Lifetime Wellness curriculum (control) regularly scheduled at control schools.
Number of subjects: 10
Study 25070447 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial immune enteral nutrition
Number of subjects: 96
Study 21952094 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ‐1b 250 µg
Number of subjects: 2244
Study 21952094 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ‐1b 500 µg
Number of subjects: 2244
Study 21952094 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ‐1b 250 µg and 500 µg
Number of subjects: 2244
Study 21952094 — intervention group
Group type: COMPARATOR
Intervention: Control (Glatiramer acetate 20 mg)
Number of subjects: 2244
Study 19254906 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 microg/day)
Number of subjects: 44
Study 19254906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 19254906 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 44
Study 19254906 — intervention group
Group type: COMPARATOR
Intervention: Inhaled budesonide and Placebo
Number of subjects: 44
Study 18091071 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (dopamine agonist)
Number of subjects: 84
Study 18091071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 15302228 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg beta‐methyl‐6‐chloromelatonin
Number of subjects: 8
Study 15302228 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg beta‐methyl‐6‐chloromelatonin
Number of subjects: 8
Study 15302228 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg beta‐methyl‐6‐chloromelatonin
Number of subjects: 8
Study 15302228 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg beta‐methyl‐6‐chloromelatonin
Number of subjects: 8
Study 15302228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15302228 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of beta‐methyl‐6‐chloromelatonin
Number of subjects: 8
Study 11587162 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate smoking cessation (n=19)
Number of subjects: 66
Study 11587162 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group (n=15)
Number of subjects: 66
Study 10223498 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg sildenafil
Number of subjects: 514
Study 10223498 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 514
Study 10223498 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil
Number of subjects: 514
Study 10223498 — intervention group
Group type: EXPERIMENTAL
Intervention: sildenafil (all doses)
Number of subjects: 514
Study 10223498 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 514
Study 7851353 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release metoclopramide (Gastromax 30 mg)
Number of subjects: 39
Study 7851353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 2520372 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid treatment under occlusive dressings for 72 hours
Number of subjects: 8
Study 2520372 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 8
Study 17894041 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose thiothixene (40 mg.)
Number of subjects: 40
Study 17894041 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose thiothixene (10 mg.)
Number of subjects: 40
Study 30635704 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS with anode on left STG/cathode on right shoulder
Number of subjects: 17
Study 30635704 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS with anode on left STG/cathode on right STG
Number of subjects: 17
Study 30635704 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 17
Study 28490942 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial approach
Number of subjects: 139
Study 28490942 — intervention group
Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 139
Study 26069137 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg (Group A)
Number of subjects: 73
Study 26069137 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg (Group B)
Number of subjects: 73
Study 26069137 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 73
Study 23276416 — intervention group
Group type: EXPERIMENTAL
Intervention: Press-fit technique
Number of subjects: 69
Study 23276416 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 69
Study 21586502 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intensive Behavioral Intervention (EIBI)
Number of subjects: 41
Study 21586502 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 41
Study 21586502 — intervention group
Group type: EXPERIMENTAL
Intervention: University-supervised interventions
Number of subjects: 41
Study 21586502 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-commissioned interventions
Number of subjects: 41
Study 18263688 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA with one aspiration
Number of subjects: 102
Study 18263688 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA with two aspirations
Number of subjects: 102
Study 18263688 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA with three aspirations
Number of subjects: 102
Study 18263688 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA with four aspirations
Number of subjects: 102
Study 18263688 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA with first or second aspiration obtaining at least one tissue core
Number of subjects: 102
Study 18263688 — intervention group
Group type: COMPARATOR
Intervention: EBUS-TBNA
Number of subjects: 102
Study 16857887 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of micronized progesterone vaginally (progesterone group)
Number of subjects: 201
Study 16857887 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of micronized progesterone and 4 mg of E2 valerate orally (progesterone/E2 group)
Number of subjects: 201
Study 11274517 — intervention group
Group type: EXPERIMENTAL
Intervention: Group randomized trials (GRTs)
Number of subjects: 0
Study 11274517 — intervention group
Group type: EXPERIMENTAL
Intervention: Various analytic methods for GRTs
Number of subjects: 0
Study 11274517 — intervention group
Group type: EXPERIMENTAL
Intervention: Design issues in GRTs
Number of subjects: 0
Study 11274517 — intervention group
Group type: EXPERIMENTAL
Intervention: Real data example
Number of subjects: 0
Study 9283776 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended insulin regimen (5 U/h continued until resolution of hyperketonemia)
Number of subjects: 22
Study 9283776 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended insulin regimen
Number of subjects: 22
Study 9283776 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin regimen (5 U/h until near-normoglycemia, then reduced rate)
Number of subjects: 22
Study 7849344 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 141
Study 3051043 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (1 mg initial dose, followed by 1 mg or 2 mg 6 hours later if needed)
Number of subjects: 50
Study 3051043 — intervention group
Group type: COMPARATOR
Intervention: Intravenous perfusion of synthetic oxytocin (starting at 1 mU/min, increased every 20 minutes)
Number of subjects: 50
Study 31092363 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1532
Study 31092363 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1532
Study 28316072 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie DASH diet
Number of subjects: 60
Study 24443001 — intervention group
Group type: EXPERIMENTAL
Intervention: 3×1000 mg rituximab
Number of subjects: 0
Study 24443001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22921855 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (TP) administered as a continuous intravenous dose of 1.3 μg/kg/h
Number of subjects: 32
Study 22921855 — intervention group
Group type: COMPARATOR
Intervention: Dopamine administered in doses up to 20 μg/kg/min
Number of subjects: 32
Study 22921855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups were monitored for hemodynamic changes and PaO(2)/FiO(2) ratio
Number of subjects: 32
Study 21399391 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg CoQ10 daily
Number of subjects: 47
Study 21399391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 19615314 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine plus American ginseng and Salviae miltiorrhizae preparations
Number of subjects: 35
Study 19615314 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 35
Study 16638761 — intervention group
Group type: EXPERIMENTAL
Intervention: Global functional impairment
Number of subjects: 245
Study 16638761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 245
Study 16638761 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired manual dexterity
Number of subjects: 245
Study 16638761 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial dysfunction
Number of subjects: 245
Study 16638761 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 245
Study 12883913 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic hydrophobic IOL (Acrysof MA30BA)
Number of subjects: 36
Study 12883913 — intervention group
Group type: COMPARATOR
Intervention: Heparin surface-modified polymethylmethacrylate IOL (Pharmacia & Upjohn 809C)
Number of subjects: 36
Study 10594199 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS lobectomy
Number of subjects: 100
Study 10594199 — intervention group
Group type: COMPARATOR
Intervention: Conventional lobectomy (open thoracotomy)
Number of subjects: 100
Study 10594199 — intervention group
Group type: COMPARATOR
Intervention: Open lobectomy
Number of subjects: 100
Study 9068769 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (100 mg/day)
Number of subjects: 141
Study 9068769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 8439073 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 40) discharged with weights < or = 2.000 gm
Number of subjects: 80
Study 8439073 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 40) discharged with weights > or = 2.000 gm
Number of subjects: 80
Study 3303402 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass (PIB)
Number of subjects: 838
Study 3303402 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 838
Study 31908205 — intervention group
Group type: COMPARATOR
Intervention: Cigarette packs with no targeting
Number of subjects: 954
Study 31908205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette packs with subtle targeting
Number of subjects: 954
Study 31908205 — intervention group
Group type: EXPERIMENTAL
Intervention: Rainbow 'pride edition' cigarette packs
Number of subjects: 954
Study 30428933 — intervention group
Group type: EXPERIMENTAL
Intervention: TPD health warnings
Number of subjects: 2400
Study 30428933 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative harm message (COMP)
Number of subjects: 2400
Study 30428933 — intervention group
Group type: COMPARATOR
Intervention: TPD presence (TPD1 vs. TPD2 vs. No-TPD)
Number of subjects: 2400
Study 30428933 — intervention group
Group type: COMPARATOR
Intervention: COMP presence (Presence vs. Absence)
Number of subjects: 2400
Study 25651896 — intervention group
Group type: EXPERIMENTAL
Intervention: Backs
Number of subjects: 41
Study 25796161 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (MP)
Number of subjects: 53
Study 25796161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioside (GM) combined with Methylprednisolone (MP)
Number of subjects: 53
Study 24055415 — intervention group
Group type: EXPERIMENTAL
Intervention: 41.6 Gy in 13 fractions over 5 weeks
Number of subjects: 4441
Study 24055415 — intervention group
Group type: EXPERIMENTAL
Intervention: 39 Gy in 13 fractions over 5 weeks
Number of subjects: 4441
Study 24055415 — intervention group
Group type: COMPARATOR
Intervention: 50 Gy in 25 fractions over 5 weeks
Number of subjects: 4441